Caplin Point Laboratories Limited (IN:CAPLIPOINT)
:CAPLIPOINT
Want to see IN:CAPLIPOINT full AI Analyst Report?
Top Page
Caplin Point Laboratories Limited
(CAPLIPOINT)
Select Model
Select Model
Rating:80Outperform
Price Target:
₹2,327.00
▲(26.06% Upside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by strong financial quality—solid growth, high margins, and an ultra-low leverage balance sheet—with supportive technical momentum. The main offset is valuation/income: a mid-range P/E with a very low dividend yield provides limited valuation support.
Positive Factors
Revenue & Margin Strength
Caplin Point’s sustained revenue growth alongside mid‑50% gross margins and net margins in the 20s indicates durable product pricing power and efficient manufacturing. This fundamental margin profile supports multi-quarter cash generation, reinvestment into capacity, and resilience versus cyclical demand swings.
Negative Factors
Margin Volatility
Recent signs that gross profit growth lagged revenue point to margin compression possibly from cost pressure or pricing challenges for certain formulations. If this structural pressure persists, it can erode free cash flow and limit funding for capacity or R&D, pressuring multi‑quarter earnings sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Strength
Caplin Point’s sustained revenue growth alongside mid‑50% gross margins and net margins in the 20s indicates durable product pricing power and efficient manufacturing. This fundamental margin profile supports multi-quarter cash generation, reinvestment into capacity, and resilience versus cyclical demand swings.
Read all positive factors
Caplin Point Laboratories Limited (CAPLIPOINT) vs. iShares MSCI India ETF (INDA)
Market Cap
₹153.26B
Dividend Yield0.31%
Average Volume (3M)3.75K
Price to Earnings (P/E)17.8
Beta (1Y)1.24
Revenue Growth12.89%
EPS Growth19.55%
CountryIN
Employees3,406
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)77.45
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)3.19
Price to Sales (P/S)5.23
P/FCF Ratio33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.6
Revenue Forecast (FY)₹23.73B
Caplin Point Laboratories Limited Business Overview & Revenue Model
Company Description
Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsu...
How the Company Makes Money
Caplin Point makes money primarily by selling pharmaceutical formulations (finished-dose generics) in domestic and international markets. Its key revenue streams include: (1) product sales of its own branded and/or unbranded generic formulations t...
Caplin Point Laboratories Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
96
Very Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.42B | 21.87B | 19.40B | 16.96B | 14.68B | 12.71B |
| Gross Profit | 11.43B | 10.50B | 11.38B | 9.40B | 7.89B | 6.99B |
| EBITDA | 7.29B | 7.61B | 6.49B | 5.51B | 4.40B | 3.94B |
| Net Income | 5.89B | 6.41B | 5.36B | 4.57B | 3.76B | 3.00B |
Balance Sheet | ||||||
| Total Assets | 35.04B | 40.45B | 32.09B | 26.98B | 21.91B | 17.36B |
| Cash, Cash Equivalents and Short-Term Investments | 10.17B | 10.07B | 9.03B | 7.88B | 6.50B | 5.13B |
| Total Debt | 85.00M | 46.10M | 50.20M | 19.70M | 54.80M | 21.30M |
| Total Liabilities | 3.05B | 4.15B | 3.22B | 3.51B | 2.84B | 2.26B |
| Stockholders Equity | 31.59B | 35.86B | 28.50B | 23.16B | 18.80B | 14.84B |
Cash Flow | ||||||
| Free Cash Flow | 1.60B | 3.37B | 2.41B | 1.73B | 779.00M | 2.46B |
| Operating Cash Flow | 2.54B | 5.85B | 4.32B | 3.18B | 2.72B | 3.37B |
| Investing Cash Flow | -2.99B | -6.45B | -3.35B | -3.20B | -2.18B | -3.77B |
| Financing Cash Flow | -460.10M | -455.90M | -383.20M | -380.70M | -281.70M | -407.10M |
Caplin Point Laboratories Limited Technical Analysis
Positive
1845.95
Price Trends
1725.03
Positive
1758.83
Positive
1902.53
Positive
Market Momentum
81.80
Negative
69.78
Neutral
83.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Positive. The current price of 1845.95 is above the 20-day moving average (MA) of 1839.05, above the 50-day MA of 1725.03, and below the 200-day MA of 1902.53, indicating a bullish trend. The MACD of 81.80 indicates Negative momentum. The RSI at 69.78 is Neutral, neither overbought nor oversold. The STOCH value of 83.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:CAPLIPOINT.
Caplin Point Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹153.26B | 17.84 | ― | 0.31% | 12.89% | 19.55% | |
76 Outperform | ₹206.99B | 26.69 | ― | 0.57% | 6.63% | -16.51% | |
69 Neutral | ₹213.32B | 42.39 | ― | 0.08% | 36.98% | 39.94% | |
66 Neutral | ₹187.93B | 18.85 | ― | 0.24% | 19.73% | 18.17% | |
62 Neutral | ₹147.95B | 19.32 | ― | 1.28% | 10.08% | 15.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:CAPLIPOINT
Caplin Point Laboratories Limited
2,022.45
-255.97
-11.23%
IN:APLLTD
Alembic Pharmaceuticals Limited
747.65
-214.24
-22.27%
IN:GRANULES
Granules India Limited
763.80
249.32
48.46%
IN:NATCOPHARM
NATCO Pharma Limited
1,172.65
300.92
34.52%
IN:NEULANDLAB
Neuland Laboratories Ltd.
16,677.65
5,489.32
49.06%
Caplin Point Laboratories Limited Corporate Events
Caplin Steriles Wins USFDA Nod for Calcium Gluconate Injection, Expands U.S. Injectables Push
May 5, 2026
Caplin Steriles, the sterile injectables arm of Caplin Point Laboratories, has received final U.S. FDA approval for its Abbreviated New Drug Application for Calcium Gluconate Injection USP in multiple vial sizes, a generic equivalent to Fresenius ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.